BioCentury | Dec 19, 2005
Company News

KeyNeurotek, Sirenade deal

...Sirenade, which was founded in 2003 through the merger of kinase companies Nadag AG and SiReen AG...
BioCentury | Dec 14, 2005
Company News

KeyNeurotek acquires Sirenade

...Sirenade , which was founded in 2003 through the merger of kinase companies Nadag and SiReen...
BioCentury | Oct 18, 2004
Emerging Company Profile

Sirenade: Disentangling Alzheimer's

...AG and SiReen AG - combining Nadag's chemical kinase platform for hit and lead generation with SiReen's...
BioCentury | Oct 18, 2004
Emerging Company Profile

Corporate Profile

...Neurology, pain Clinical status: Phase II Founded: 2003 through the merger of Nadag AG and SiReen AG...
BioCentury | Jul 12, 2004
Company News

Sirenade, Solvay SA deal

...service payments and is eligible for milestones. In January, German drug discovery companies Nadag and SiReen...
BioCentury | Jul 7, 2004
Company News

Sirenade, Solvay structural biology deal

...service payments and is eligible for milestones. In January, German drug discovery companies Nadag and SiReen...
BioCentury | Jan 19, 2004
Company News

Nadag AG, Sireen deal

...Drug discovery companies Nadag and SiReen will merge in a stock transaction to form Sirenade Pharmaceuticals...
...AG , which will focus on CNS and oncology indications. The new company will combine SiReen's...
...platform for hit and lead generation. Nadag has one preclinical Alzheimer's disease (AD) program, and SiReen...
BioCentury | Jan 13, 2004
Company News

Nadag, SiReen merging

...Drug discovery companies Nadag (Munich, Germany) and SiReen (Munich, Germany) will merge to form Sirenade Pharmaceuticals...
...Sirenade Pharmaceuticals, which will focus on CNS and oncology indications. The new company will combine SiReen's...
...platform for hit and lead generation. Nadag has one preclinical Alzheimer's disease (AD) program, and SiReen...
BioCentury | Mar 31, 2003
Tools & Techniques

Excigen provides an electric opportunity; SiReen's protein mutagenesis

...to treat peripheral vascular disease and as an adjunct to bypass surgery. - Aimee Dingwell SiReen's...
...chemistry specific only to a protein target when little is known about other similar proteins. SiReen AG...
...information to select active compounds that SiReen will synthesize to create focused libraries (see B3). SiReen...
BioCentury | Mar 31, 2003
Company News

Evotec OAI AG, Sireen deal

...genomics technology to perform library synthesis and compound refinement. SiReen will pay EVT service fees. SiReen...
...2002 target identification deal (see BioCentury, April 1, 2002). Evotec OAI AG (FSE:EVT), Hamburg, Germany SiReen AG...
Items per page:
1 - 10 of 14
BioCentury | Dec 19, 2005
Company News

KeyNeurotek, Sirenade deal

...Sirenade, which was founded in 2003 through the merger of kinase companies Nadag AG and SiReen AG...
BioCentury | Dec 14, 2005
Company News

KeyNeurotek acquires Sirenade

...Sirenade , which was founded in 2003 through the merger of kinase companies Nadag and SiReen...
BioCentury | Oct 18, 2004
Emerging Company Profile

Sirenade: Disentangling Alzheimer's

...AG and SiReen AG - combining Nadag's chemical kinase platform for hit and lead generation with SiReen's...
BioCentury | Oct 18, 2004
Emerging Company Profile

Corporate Profile

...Neurology, pain Clinical status: Phase II Founded: 2003 through the merger of Nadag AG and SiReen AG...
BioCentury | Jul 12, 2004
Company News

Sirenade, Solvay SA deal

...service payments and is eligible for milestones. In January, German drug discovery companies Nadag and SiReen...
BioCentury | Jul 7, 2004
Company News

Sirenade, Solvay structural biology deal

...service payments and is eligible for milestones. In January, German drug discovery companies Nadag and SiReen...
BioCentury | Jan 19, 2004
Company News

Nadag AG, Sireen deal

...Drug discovery companies Nadag and SiReen will merge in a stock transaction to form Sirenade Pharmaceuticals...
...AG , which will focus on CNS and oncology indications. The new company will combine SiReen's...
...platform for hit and lead generation. Nadag has one preclinical Alzheimer's disease (AD) program, and SiReen...
BioCentury | Jan 13, 2004
Company News

Nadag, SiReen merging

...Drug discovery companies Nadag (Munich, Germany) and SiReen (Munich, Germany) will merge to form Sirenade Pharmaceuticals...
...Sirenade Pharmaceuticals, which will focus on CNS and oncology indications. The new company will combine SiReen's...
...platform for hit and lead generation. Nadag has one preclinical Alzheimer's disease (AD) program, and SiReen...
BioCentury | Mar 31, 2003
Tools & Techniques

Excigen provides an electric opportunity; SiReen's protein mutagenesis

...to treat peripheral vascular disease and as an adjunct to bypass surgery. - Aimee Dingwell SiReen's...
...chemistry specific only to a protein target when little is known about other similar proteins. SiReen AG...
...information to select active compounds that SiReen will synthesize to create focused libraries (see B3). SiReen...
BioCentury | Mar 31, 2003
Company News

Evotec OAI AG, Sireen deal

...genomics technology to perform library synthesis and compound refinement. SiReen will pay EVT service fees. SiReen...
...2002 target identification deal (see BioCentury, April 1, 2002). Evotec OAI AG (FSE:EVT), Hamburg, Germany SiReen AG...
Items per page:
1 - 10 of 14